XOMA Corporation (XOMA) Long-Term Debt to Capital Ratio

XOMA Royalty (XOMA) relies on a powerful defensive barrier by accumulating royalty rights to promising molecules within the portfolios of pharmaceutical behemoths. The business model is based on acquiring future royalty streams, which eliminates development costs amid inelastic demand for medications. This price chart, where the indicator equals 0.98, demonstrates the price action of an asset that could be adversely affected by global conflicts disrupting the operations of research centers.

Professional selection of sustainable assets requires an analysis of long-term leverage to assess insolvency risk while maintaining profitability. This long-term debt-to-equity ratio correlates liabilities with a term exceeding one year against net assets, which, for the non-cyclical royalty business of XOMA, confirms financial autonomy and independence from macroeconomic GDP fluctuations.